Delong Meng
Cancer researcher at UCSF who led the preclinical test of RMC-6272, a drug that blocks mTORC1 much more strongly than mTORC2, in drug-resistant breast cancer
Department of Bioengineering and Therapeutic Sciences, University of California San Francisco (at the time of the 2023 study, with Sourav Bandyopadhyay)
Delong Meng is the first author of MEN2023, an Oncogene paper from Sourav Bandyopadhyay's group at UCSF, written with colleagues at Revolution Medicines, the company that makes the drug. mTOR works in two complexes. mTORC1 drives growth, and in many breast cancers it stays switched on because of mutations in PIK3CA or PTEN. Older drugs either block mTORC1 only partly, like rapamycin, which misses the target 4E-BP1, or block both complexes, which causes side effects such as high blood sugar. RMC-6272 is a bi-steric inhibitor: one molecule that grips mTOR at two sites at once. It is more than 25 times more selective for mTORC1 than for mTORC2 and shuts mTORC1 down completely, including its control of 4E-BP1.
In the study the drug killed ER-positive breast cancer cell lines, especially those with PIK3CA or PTEN mutations, and still worked in models that had become resistant to hormone therapy and to CDK4/6 inhibitors. The tests used cell lines and patient tumours grown in mice (PDX models), so they are preclinical. The paper laid groundwork for the related drug RMC-5552, which has gone into clinical trials.
PubMed shows no other paper that can be tied to this name with the same co-authors, and no official profile was found, so the current position could not be confirmed. The affiliation shown is the one on the Atlas paper.
Milestones in the Atlas
A selection, not a full bibliography: only papers that meet the Atlas inclusion criteria.
| Year | Evidence | Study |
|---|---|---|
| 2023 | A | A bi-steric mTORC1-selective inhibitor overcomes drug resistance in breast cancer MEN2023 First author: showed that the mTORC1-selective bi-steric inhibitor RMC-6272 overcomes hormone- and CDK4/6-inhibitor resistance in breast cancer cell lines and PDX models. |
Co-authors in the Atlas 3
People with a profile here who share at least one study with Delong Meng.
ShowHide
- Hani Goodarzi Systems biologist at UCSF and the Arc Institute who combines computation and experiments to find hidden gene-regulation programs that drive cancer, and a co-author of two Atlas studies on mTORC1 in drug-resistant cancers
- Sourav Bandyopadhyay Uses functional genomics, drug screens and proteomics to understand why breast and lung cancers become resistant to drugs, including drugs that target the mTOR pathway.
- Yu Chi Yang Scientist at Revolution Medicines who worked on the company's bi-steric mTORC1-selective inhibitors, from the breast cancer lab studies of RMC-6272 to the first trial of RMC-5552 in patients
Every researcher with a profile →
Thank you. That helps us know which pages have been read by someone who knows the work.
Thank you. We will check it and correct the page.
Thank you. Your answer was counted anonymously.